|
A cost analysis of managing cancer-related pain among hospitalized US cancer patients. |
|
|
Consulting or Advisory Role - AstraZeneca; Conjupro Biotherapeutics; Exelixis; Ipsen |
Research Funding - Acetylon Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Five Prime Therapeutics (Inst); Ipsen (Inst); Taiho Pharmaceutical (Inst); Tesaro (Inst) |
Travel, Accommodations, Expenses - Exelixis |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Array BioPHarma |
Research Funding - Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Lycera (Inst); RAPT Therapeutics (Inst); RAPT Therapeutics (Inst); Seagen (Inst); Symphogen (Inst); Vaccinex (Inst) |
Travel, Accommodations, Expenses - Array BioPharma |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Eisai; Ipsen |
Research Funding - Bristol-Myers Squibb-Ono Pharmaceutical (Inst); Eisai (Inst); Merck Sharp & Dohme (Inst); Polaris (Inst); RedHill Biopharma (Inst); Tesaro (Inst); Xencor (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bayer; Lexicon; RTI Health Solutions |
Consulting or Advisory Role - Bayer; BTG; Loxo; Merrimack; RTI Health Solutions |
Speakers' Bureau - Bristol-Myers Squibb; Lexicon |
Research Funding - AstraZeneca/MedImmune (Inst); AVEO (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Cleave Biosciences (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Hoosier Cancer Research Network (Inst); ICON Clinical Research (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); PPD (Inst); Taiho Pharmaceutical (Inst); Xencor (Inst) |
Other Relationship - ERYTECH Pharma; Exelixis |